Prosecution Insights
Last updated: April 19, 2026

Hangzhou Dac Biotech Co. Ltd.

9 pending office actions

Portfolio Summary

9
Total Pending OAs
6
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18156709 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS PUTTLITZ, KARL J 1646 Non-Final OA Jan 19, 2023
18156748 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS VAN DRUFF, SYDNEY 1643 Final Rejection Jan 19, 2023
18001899 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CANELLA, KAREN A 1643 Non-Final OA Dec 15, 2022
17623360 CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING JARRELL, NOBLE E 1699 Final Rejection Dec 28, 2021
17622360 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS PUTTLITZ, KARL J 1646 Final Rejection Dec 23, 2021
17390064 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE COUGHLIN, MATTHEW P 1626 Final Rejection Jul 30, 2021
17426813 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS CANELLA, KAREN A 1643 Non-Final OA Jul 29, 2021
17284091 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP STONEBRAKER, ALYSSA RAE 1642 Final Rejection Apr 09, 2021
17256034 A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES BRAUN, MADELINE E 1624 Final Rejection Dec 24, 2020

Managing Hangzhou Dac Biotech Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month